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30 Abstract:
31 The complexity and heterogeneity of patients with multimorbidity and polypharmacy renders traditional 
32 disease-oriented guidelines often inadequate and complicates clinical decision making. To address this 
33 challenge, guidelines have been developed on multimorbidity or polypharmacy. To systematically 
34 analyze their recommendations, we conducted a systematic guideline review using the Ariadne 
35 principles for managing multimorbidity as analytical framework. The information synthesis included a 
36 multi-step consensus process involving 18 multi-disciplinary experts from seven countries. We included 
37 eight guidelines (four each on multimorbidity and polypharmacy) and extracted about 250 
38 recommendations. The guideline addressed (1) the identification of the target population (risk factors); 
39 (2) the assessment of interacting conditions and treatments: medical history, clinical and psychosocial 
40 assessment including physiological status and frailty, reviews of medication and encounters with 
41 healthcare providers highlighting informational continuity; (3) the need to incorporate patient 
42 preferences and goal setting: eliciting preferences and expectations, the process of shared decision 
43 making in relation to treatment options and the level of involvement of patients and carers; (4) 
44 individualized management: guiding principles on optimization of treatment benefits over possible 
45 harms, treatment communication and the information content of medication/care plans; (5) monitoring 
46 and follow-up: strategies in care planning, self-management and medication-related aspects, 
47 communication with patients including safety instructions and adherence, coordination of care regarding 
48 referral and discharge management, medication appropriateness and safety concerns. The spectrum of 
49 clinical and self-management issues varied from guiding principles to specific recommendations and 
50 tools providing actionable support. The limited availability of reliable risk prediction models, feasible 
51 interventions of proven effectiveness and decision aids, and limited consensus on appropriate outcomes 
52 of care highlight major research deficits. An integrated approach to both multimorbidity and 
53 polypharmacy should be considered in future guidelines.
54
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62 Background:
63 Family physicians care for patients with multiple conditions, known as multimorbidity [1], in up to 80% of 
64 their consultations [2], while in geriatrics this is the case for essentially all patients. The presence of 
65 multiple conditions makes the patient’s management challenging in a number of ways. First, the 
66 potentially complex interlinked pathophysiological pathways underlying the conditions need to be taken 
67 into account in diagnosis and monitoring. Secondly, when developing care plans for these patients, the 
68 potential risks and benefits of interventions need to be taken into account both for each condition and 
69 across diseases. Furthermore, some concurrent conditions may not necessarily have a clinical impact but 
70 may complicate interpretation of symptom presentations. All this makes the process more difficult and 
71 the outcomes less certain [3]. 
72 Patients with multiple conditions commonly take multiple prescriptions (polypharmacy) [4], which 
73 further increase complexity. Firstly, by increasing the potential for interactions between diseases and 
74 treatments medication choice is less straightforward. Secondly, by increasing the possibility that 
75 additional medications will be prescribed to counteract side effects prescribing cascades may occur. 
76 Physicians involved in caring for these patients report that current decision support is inadequate to 
77 optimize benefits and minimize harms in these patients with complex needs [5].
78 More than a decade ago, attention was drawn to the fact that the application of individual disease-
79 oriented guidelines to patients with multimorbidity was not feasible and potentially harmful [6]. In 
80 addition to the potential harm from interactions between diseases and treatments, there is also an often 
81 unrecognized treatment burden [7, 8]. However, other studies indicate that adherence to clinical 
82 practice guidelines has the potential to improve outcomes for a range of chronic conditions including 
83 chronic heart failure and COPD, which commonly occur in people with multimorbidity [9-13]. 
84 Current approaches to support clinical decision making in multimorbidity and polypharmacy tend to 
85 adapt condition specific guidelines to take into account co-occurring problems; or to present principles 
86 on how to make a conscious use of disease oriented guidelines [14-16]. More recently, clinical practice 
87 guidelines for the management of multimorbidity and polypharmacy have been developed [17]. 
88 However, questions arise whether these guidelines provide relevant support for clinical decision making 
89 considering the vast heterogeneity of diseases, their potential combinations and varying degrees of 
90 disease severity in these patients.
91 We therefore aimed to identify and analyze available evidence-based clinical practice guidelines for 
92 multimorbidity or polypharmacy in order to investigate the clinical decision support they provide and the 
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93 key concepts they address. To facilitate the interpretation and actionability of the findings, we used the 
94 previously published Ariadne principles [15], which provide a framework to guide care delivery in 
95 patients with multimorbidity. At the core, the sharing of realistic treatment goals by physicians and 
96 patients results from i) an interaction assessment, i.e., the thorough assessment of diseases and 
97 treatments including their potential interactions, the patient’s clinical status, their context as well as a 
98 consideration of treatment burden; ii) the prioritization of health problems taking into account the 
99 patient’s preferences – his or her most and least desired outcomes; and iii) an individualized 
100 management plan which outlines the best options of care in diagnostics, treatment, and prevention to 
101 achieve the goals; iv) goal attainment is followed-up with a re-assessment in planned visits and v) the 
102 occurrence of new or changed conditions, such as an increase in severity, or a changed context may 
103 trigger a re-evaluation of the previous steps[15].
104
105
106 Methods:
107 We conducted a modified systematic guideline review [18] followed by a workshop-based consensus 
108 meeting with multidisciplinary experts from North America and Europe.
109
110 Literature Search and Selection
111 We conducted a systematic search for existing clinical practice guidelines in the electronic databases 
112 MEDLINE, The Cochrane Library, Health Services/Technology Assessment Texts (HSTAT), ‘Turning 
113 Research Into Practice’ (TRIP) and Guideline International Network (G-I-N) database, as well as in the 
114 National Guideline Clearinghouse combining controlled terms and free text words, such as comorbidity, 
115 multimorbidity, multiple conditions, polypharmacy, multiple drugs, multiple medications and older 
116 adults. We conducted the searches in February and March 2018, dated back to the database inception. 
117 In addition, we searched websites of guideline producing organizations including geriatric and primary 
118 care societies (the complete list is provided in Web-Supplement 1).
119 We included comprehensive guidelines or guideline-like documents on multimorbidity and 
120 polypharmacy, if they were “systematically developed statements to assist practitioner and patient 
121 decisions about appropriate health care for specific clinical circumstances" [19], if their purpose was "to 
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122 make explicit recommendations with a definite intent to influence what clinicians do" [20] and if they 
123 were endorsed by guideline producing organizations or physicians’ colleges. We accepted definitions of 
124 multimorbidity and polypharmacy used in individual guidelines and no language restriction was applied. 
125 We excluded disease-oriented guidelines (e.g., on osteoporosis management in elderly), guidelines with 
126 a narrow focus (e.g., on de-prescribing of potentially inappropriate medications in the elderly, using 
127 specific indicators such as Beers criteria [21]) or which did not report any methods of systematic 
128 development (a systematic literature search for at least some of the addressed questions had to be 
129 reported). Searches and selection of guidelines were conducted by two independent reviewers (AIGG 
130 and TSN).
131
132 Quality Appraisal
133 We (AIGG, MSB, JWB and TSN) appraised the quality of the guidelines using the MiChe Checklist [22, 23], 
134 which consists of eight specific questions (recommendations, audience, objectives, conflict of interest, 
135 systematic search, unambiguity, evaluation of benefits, and update) and two holistic items (overall 
136 assessment and recommendation for further use). Each specific question is answered as “Yes”, “No” or 
137 “To some extent”, the overall assessment is rated on a Likert scale ranging from “1”=very poor to 
138 “7”=very good, and the recommendation is rated with “Yes”, “Yes, with certain reservations”, and “No”.
139
140 Data extraction
141 We (AIGG, CM, JWB, MSB, TSN) extracted data from the guidelines according to a pre-defined 
142 framework based on the Ariadne principles [15], which encompassed recommendations on (i) 
143 interaction assessment, (ii) prioritization of patient’s preferences and agreement on shared treatment 
144 goals, (iii) individualized management of patients to achieve these goals and (iv) monitoring and follow-
145 up of goal attainment. To fit the aim of the framework analysis, (v) (‘trigger events’ to (re)start the 
146 Ariadne principles) was reframed as methods for ’identification of the target population’. 
147 Additional information on each guideline was extracted: the source, the year of publication, the country 
148 of origin, underlying concepts including definitions of multimorbidity and polypharmacy, the target 
149 setting, the target population and patient-related outcomes. For each topic of the a priori defined 
150 Ariadne framework, we (AIGG, CM, JWB, MSB, TSN) extracted the data into evidence tables using a 
151 standardized format, which included recommendation(s), level of evidence (LoE) and grade of 
152 recommendation (GoR) as provided in the guideline. When recommendations addressed more than one 
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153 domain of the framework, we (CM, JWB) agreed upon the domain that best matched the 
154 recommendation to avoid duplicates.
155
156 Analysis 
157 The numbers of recommendations per topic and per guideline were described. We (AIGG, CM, JWB, 
158 SMS, TSN) conducted a thematic analysis, assigned categories and aggregated the recommendations as 
159 outlined above using the Ariadne framework.
160
161 Expert consensus process
162 We discussed the results of the thematic synthesis at a two-day meeting in May 2018. This meeting 
163 included a symposium, in which the background to the topic was elucidated and a workshop with 18 
164 invited multidisciplinary experts – some of them with more than one area of expertise: geriatrics (7), 
165 primary care (6), public health and health services research (5), epidemiology (4) and 
166 pharmacy/pharmacology (2) from seven countries (Sweden (5), UK (4), USA (3), Italy and the Netherlands 
167 (2), Germany and Ireland (1)). The group discussion was audio-recorded and transcribed and served as 
168 triangulation of the thematic analysis. The results of the guideline review and the group discussion were 
169 agreed upon and synthetized by all authors.
170
171
172 Results:
173 In total, we included eight guidelines, four on multimorbidity and four on polypharmacy [24-31] (Figure 
174 1; the list of excluded guidelines with reasons for exclusion is provided in Web-Supplement 2). Three 
175 guidelines were developed in the UK, two in Germany and one each in the US, the Netherlands and 
176 Mexico (Table 1 [32, 33]). Four guidelines were of very good quality, the remaining had minor 
177 shortcomings - mainly due to a limited reporting quality, including two which did not report on update 
178 procedures and therefore scored lowest in that domain (for details of the quality appraisal see Web-
179 Supplement 3).
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180 In total, we extracted 246 recommendations (median: 27 recommendations per guideline (IQR: 13 to 52, 
181 range: 7-57)). The most common recommendations addressed the need for a thorough assessment of 
182 interactions and individualized management of patients (n=69 recommendations each), followed by 
183 identifying patient’s preferences and goal setting (n=50), monitoring and follow-up (n=32), and 
184 identification of the target population (n=26) (Figure 2). Some of the recommendations were not specific 
185 to a single domain, for example, recommendations on individualized management also incorporated 
186 elements of monitoring and follow up.
187
188 [About here: Figure 1: Results of the search and selection process (flow chart)]
189
190 [About here: Table 1: Characteristics of included guidelines]
191
192 [About here: Figure 2: Distribution of recommendations per topic and guideline]
193
194 Identification of the target population
195 In one guideline, a systematic search for existing risk predicting models revealed many models for 
196 patients with multimorbidity but not for patients with polypharmacy [28]. This guideline recommended 
197 the identification of adults with multimorbidity at risk of adverse events (e.g., unplanned hospital 
198 admission or admission to a care home) using prognostic models – either opportunistically during 
199 routine care or proactively using the electronic medical record (EMR) [28]. Five guidelines provided 
200 information about risk factors for negative health outcomes  covering different dimensions, such as 
201 condition-, medication-, adherence-related, and risks related to social context and health care utilization 
202 [25, 26, 28-30]. Condition-related risk factors included the presence of certain chronic diseases such as 
203 depression, dementia or cognitive decline, combinations of chronic mental and physical diseases such as 
204 diabetes and schizophrenia, the presence of conditions or events such as frailty, falls, non-specific 
205 symptoms and a worsening of health [25, 28-30]. Medication-related risks referred to drugs with a 
206 narrow therapeutic range, high potential for drug-drug interactions, the need for constant monitoring, 
207 psychotropic drugs and where patients received a suboptimal benefit from pharmaceutical treatment 
208 [26, 29]. Patients with non-adherence, difficulties managing their treatment regimen due to a high 
209 treatment burden or administration problems were also regarded as being at risk [25, 28, 29]. Social risk 
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210 factors included problems managing day-to-day activities, not living independently, limited ability to 
211 understand treatment recommendations (e.g., language problems and health literacy ), advanced age 
212 and limited access to health care [25, 28-30]. The involvement of multiple and uncoordinated health care 
213 professionals and low uptake of care plans was noted to increase unplanned hospital admissions and 
214 emergency care [25, 28, 29].
215
216 Interaction assessment
217 According to the Ariadne Principles the interaction assessment should be conducted as a thorough 
218 assessment of diseases (including severity and impact on quality of life and functioning) and treatments 
219 (including potential interactions, adverse drug reactions, under-use and adherence), and of the clinical 
220 status and psychosocial context of the patient [15]. Seven guidelines addressed this principle, covering 
221 the medical history, a clinical and psychosocial assessment, a medication review and consideration of 
222 previous health services utilization [25-31]. Regarding the medical history, the documentation of all 
223 known diagnoses and conditions as well as existing laboratory test results and medication-related 
224 problems in the electronic medical record was recommended [25, 29]. One guideline [25] recommended 
225 the use of a structured questionnaire [34] about medication use, problems, experiences, worries and 
226 expectations. The clinical assessment included identification of a wide range of health problems as well 
227 as an assessment of physiological status and frailty [27, 28]. Recommendations on a medication review 
228 were at the core of the included polypharmacy guidelines, but were also addressed in the multimorbidity 
229 guidelines. One of them stressed the importance of informational continuity, in order to explore 
230 encounters with other physicians or health care professionals and changes in management over time 
231 [29] (Textbox 1).
232
233 [About here: 
234 Textbox 1: Key recommendations on interaction assessment
235 Guiding principles
236  Assess diseases, health problems, clinical and functional status, pharmacological and non-
237 pharmacological treatment including potential interactions between diseases and treatments as well 
238 as the burden for the patient and take into account his/her psychosocial context [25-31].
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239  Involve patients and their family members or carers, where appropriate, in the assessment process, 
240 and clarify and resolve misconceptions [26, 31].
241  Explore patient’s contacts with other health care professionals and any related changes in 
242 management and consider using information technology support and a multidisciplinary team-based 
243 approach [26, 28, 29, 31].
244 Specific recommendations on clinical management
245  Clinical assessment: Assess the management of health problems such as chronic pain, depression 
246 and anxiety, the presence of incontinence, the physiological and functional status and whether there 
247 are nutritional and hydration requirements [27, 28].
248  Medication review: Evaluate the risk-benefit of each drug, its possible interactions and adverse 
249 effects, adherence to treatment and unmet needs and be aware of possible prescribing cascades [29, 
250 30]. Assess the use of prescriptions, over-the-counter and food supplements or medicinal herbs and 
251 the actual implementation of a medication plan [29, 30]. Undertake a medication review regularly 
252 once a year; more often if needed, for example in relation to hospital stays: on admission, transfers 
253 between wards and at discharge [27, 29]. Use multiple methods such as health record reviews, 
254 patient surveys during consultations in practice or home visits and direct observation of medicines 
255 administration [26-29].
256 Specific recommendations on self-management support†
257  Establish disease and treatment burden, its effect on day-to-day life including mental health, general 
258 wellbeing and quality of life [28]. Establish additional burden arising from caring responsibilities [27]. 
259 These features need to be incorporated when considering patients’ capacity and the supports 
260 needed for self-management of long-term conditions and treatments [27].
261 Toolbox
262 Clinical assessment
263  Instruments determining patient capacity and vulnerability to interactions, such as gait speed, self-
264 reported health status, the PRISMA-7 questionnaire [35] (primary care), the 'Timed Up and Go' test 
265 [36], the Physical Activity Scale for the Elderly [37] (hospital outpatients) and Comprehensive 
266 Geriatric Assessment, CGA [38] (hospitals).
267 Medication assessment
268  Instruments based on implicit criteria, such as MAI (Medication Appropriateness Index) [39], ACOVE 
269 (Assessing Care of Vulnerable Elders) [40], and the STRIP method (Systematic Tool to Reduce 
270 Inappropriate Prescribing) [28].
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271  Instruments based on explicit criteria, such as the STOPP (Screening Tool of Older Person's 
272 Prescriptions), START (Screening Tool to Alert doctors to Right Treatment) [41, 42], PIM lists 
273 (Potentially Inappropriate Medications, e.g., Beers criteria, EU-PIM list) [21, 43], FORTA (Fit for The 
274 Aged) [44-46], QT drug lists [47], databases on interactions, dosage adaption according to renal 
275 function and fall risk increasing drugs.
276
277 †We defined self-management support as the care and encouragement provided to people with chronic 
278 conditions and their families to help them understand their central role in managing their illness, make 
279 informed decision about care and engage in healthy behaviors (MacColl Center [50]).
280 End of Textbox 1]
281
282 Patient’s preferences, prioritization and goal setting
283 All but one of the guidelines provided recommendations on eliciting patient preferences and 
284 expectations, including guidance on the level of involvement of patients and carers. The 
285 recommendations also focus on the process of shared decision making in relation to treatment options 
286 and the way they are communicated [24-29, 31]. Two guidelines provided specific recommendations 
287 regarding decision aids as tools to support shared decision-making [26, 28]. Additionally, one guideline 
288 referred to the need for specific skills and expertise in the use of patient decision aids [26] (Textbox 2).
289
290 [About here: 
291 Textbox 2: Key recommendations on eliciting patient’s preferences and sharing realistic treatment goals.
292 Guiding principles
293  Patients should be encouraged to express their personal values, aims and priorities. The attitude of 
294 the patient regarding the treatment and its potential benefit has to be explored [26, 28, 31]. This 
295 includes addressing medical, psychological, emotional, social, personal, sexual, spiritual, cultural 
296 needs, vision, hearing and communication needs, environmental care needs and palliative and end 
297 of life care needs [24, 27].
298 Specific recommendations on clinical management
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299  Discuss with the person the purpose of the approach to care, for example, to improve quality of life 
300 and function. This might include reducing treatment burden and optimizing care and support by 
301 identifying possible improvements in medication and reducing inappropriate or medication with 
302 negative effect [28].
303  The process of eliciting patient preferences requires several steps: 1) recognize when the patient 
304 with multimorbidity is facing a “preference sensitive” decision; 2) ensure patients with 
305 multimorbidity are adequately informed about the expected benefits and harms and 3) elicit patient 
306 preferences only after the individual with multimorbidity is sufficiently informed [24].
307  Explore patient’s expectations and objectives about treatments before prescribing [29].
308  Find out what level of involvement in decision-making the person would like and avoid making 
309 assumptions about this [26].
310  Use the best available evidence when making decisions with or for individuals, together with the 
311 clinical expertise and the person’s values and preferences [26].
312 Specific recommendations on self-management support
313  Encourage patients with multimorbidity to clarify what is important to them, including their personal 
314 goals, values and priorities [28].
315 Toolbox
316  Use a patient decision aid to help them make a preference-sensitive decision that involves trade-offs 
317 between benefits and harms, if available in high quality and appropriate in the context of the 
318 consultation as a whole [26].
319 End of Textbox 2]
320
321 Individualized management
322 All guidelines provided recommendations on this topic. Guiding principles referred to the optimization of 
323 treatment benefits over possible harms in pharmaceutical and non-pharmaceutical interventions. They 
324 also referred to information that should be included in medication plans – and, in wider care plans, 
325 including social and tele-healthcare [24, 26-30]. Recommendations on treatment communication (with 
326 or without direct consideration of self-management support) was a strong focus in four guidelines [26-
327 29] and the coordination of care was addressed in more than half of guidelines [24, 26-29, 31]. Self-
328 management support was addressed indirectly in relation to individualized management in half of the 
Page 13 of 73 Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14
329 guidelines [26-29]. The guidelines which addressed this issue focused primarily on self-management 
330 support for medicines management and support with care coordination (Textbox 3).
331
332 [About here: 
333 Textbox 3: Key recommendations on individualized management
334 Guiding principles
335  Use strategies for choosing therapies that optimize benefit, minimize harm, and enhance quality of 
336 life for patients with multimorbidity and consider treatment burden, complexity and feasibility [24, 
337 28].
338  Consider the applicability and quality of evidence such as study population, study duration, benefits 
339 in terms of absolute risk reduction and time horizon. Studies in younger patients without 
340 multimorbidity and polypharmacy and with short follow-up times and relative risk reduction may 
341 overestimate benefits and underestimate harms, and time horizon to benefit may be too late to 
342 achieve relevant treatment effects in older patients with multimorbidity and polypharmacy [24, 28, 
343 30].
344  In deprescribing medication(s), follow a systematic approach including identification and 
345 prioritization of medicines to be discontinued, stopping one at a time and consideration of tapering 
346 dosage rather than stopping, and planning and communicating with patients (and caregivers, if 
347 necessary) [29].
348  Ensure care plans are tailored to each person, giving them choice and control and recognizing the 
349 inter-related nature of multiple long-term conditions [27].
350  Health professionals involved in the treatment of patients with multimorbidity should share relevant 
351 information about the person and their medicines – in particular when patients are transferred to 
352 another care setting [27, 31].
353 Specific recommendations on clinical management
354  Be aware that the management of risk factors for future disease can be a major treatment burden 
355 for people with multimorbidity and should be carefully considered when optimizing care [28].
356  When prescribing medications such as statins and bisphosphonates, be aware that they may only 
357 provide benefit to elderly patients who have estimated survival greater than five years [30].
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358  The selection of a primary pharmacy is recommended to support the coordination of self-
359 administered drugs with regard to dosage instructions and overall medication regimens, particularly 
360 when there are multiple prescribers [29].
361  Ensure there is community based multidisciplinary support for patients with multimorbidity with 
362 social care needs which might include, for example, a physiotherapist or occupational therapist, a 
363 mental health social worker or psychiatrist, and community based services [27].
364 Specific recommendations on self-management support
365  Consider using an individualized patient-held medication plan that should include information on 
366 drugs and specific instruction for usage; if dosage is 'as needed', exact information about indication 
367 and individual dosage must be provided (single dose, interval and maximal daily dosage); in short-
368 term prescriptions, the prospective end date should be specified and information about medication 
369 history and reduced renal function should be included when indicated [29].
370  Develop care plans that address ongoing medical and social care needs for individual patients that 
371 focus on enhancing social connectedness and community involvement and also ensuring that carers’ 
372 needs are taken into consideration and that these care plans do not add to treatment burden [26-
373 28].
374  Ensure ongoing and adequate communication, in particular around medicines and wider care plans 
375 with identification of perceived benefits and ensuring patient involvement in the process [26-28].
376  Consider with the person whether there are tele-healthcare options that may support them to make 
377 informed choices to help them manage their conditions, as well as other potential benefits, risks and 
378 costs [27].
379  Consider the use of named care coordinators who can agree a course of action with patients and 
380 their carers if these needs cannot be addressed by existing health and social care professionals. This 
381 may be particularly important at times of transition, for example when considering moving to a care 
382 home [27].
383 Toolbox
384  Computerized decision support systems (CDSS) that support decision-making and prescribing but do 
385 not replace clinical judgment; and options for tele-healthcare [26, 27].
386 End of Textbox 3]
387
388 Monitoring and follow-up
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389 In five guidelines, aspects of follow-up and monitoring of treatment effects as well as goal attainment 
390 were addressed [25-29]. Recommendations covered strategies in care planning, self-management and 
391 medication-related aspects, the communication with patients including patient information and safety 
392 instructions as well as adherence, the coordination of care regarding medication appropriateness and 
393 safety concerns, possible collaboration with pharmacies, the involvement of care coordinators, referrals 
394 and discharge management [25-29]. Additionally, organizational or health care professionals’ 
395 responsibilities with regard to follow-up of medication-related aspects and the specific conditions in care 
396 homes were addressed in two guidelines [26, 27] (Textbox 4).
397
398 [About here:
399 Textbox 4: Key recommendations on monitoring and follow-up
400 Guiding principles
401  Review and update medication / care plans regularly to recognize and record changes in needs [25-
402 29].
403 Specific recommendations on clinical management
404  Monitor treatment effects and clinical parameters, as well as side effects at follow-up appointments. 
405 Check for non-specific symptoms as potential indicators of complications resulting from treatment 
406 changes such as dry mouth, weakness / exhaustion / fatigue, drowsiness, reduced alertness, sleep 
407 disturbances, motor disorders, tremors, falls; constipation, diarrhea, incontinence, loss of appetite, 
408 nausea; skin rashes, itching; depression or lack of interest in usual activities, confusion (temporary or 
409 chronic), hallucinations, fear and agitation, vertigo, tinnitus and control clinical parameters (e.g., 
410 health examination, if necessary lab tests, ECG). Consider increasing the frequency of follow-up visits 
411 following treatment changes [29].
412  Monitor treatment after discharge: due to the (usually) short duration of a hospital stay, newly 
413 introduced medications may not have reached steady state at discharge, because inpatient care is 
414 frequently shorter than 4 to 5 half-lives of prescribed drugs. Effectiveness and side effects cannot 
415 necessarily be properly assessed in hospital [29].
416  Monitor ongoing treatment including demonstrations of medication administration (e.g., inhalers) 
417 and effective forms of self-monitoring [29].
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418  Consider continuing to offer information and support to people and their carers, even if they have 
419 declined this previously, recognizing that long-term conditions can be changeable or progressive, 
420 and people's information needs may change [26].
421 Specific recommendations on self-management support
422  Review the self-management plan to ensure the person does not have problems using it [26].
423  Health and social care providers should explain to patients, and their family members or carers 
424 where appropriate, how to identify and report medicines-related patient safety incidents that arise 
425 during follow-up periods [26].
426  Self-management plans could include specific arrangements about follow-up to review the decisions 
427 made [28].
428 End of Textbox 4]
429
430
431 Discussion
432 Summary of included guidelines
433 Our review identified eight comprehensive guidelines addressing older patients with multimorbidity or 
434 polypharmacy. Many guidelines had to be excluded, mainly due to a lack of reporting of systematic 
435 search strategies. The vast majority of the included guidelines were of good quality according to the 
436 MiChe checklist [22, 23]. Interestingly, only three out of eight guidelines used levels of evidence and 
437 grades of recommendations, despite the recognition of their importance [48]. This may reflect the fact 
438 that evidence for effective interventions in this population is scarce and that expert consensus may often 
439 represent the best available evidence. However, this has also been the case for disease-specific 
440 guidelines. For example in chronic heart failure, a review found that about half of the guideline 
441 recommendations were consensus based [18]. There is a clear need to prioritize research to generate 
442 evidence for effective interventions in ‘real world-patients’.
443 The recommendations included in the guidelines covered a broad spectrum of aspects related to clinical 
444 management and self-management and included recommendations beyond traditional realms of clinical 
445 guidelines (e.g., regarding structural requirements of organizations, knowledge and skills of different 
446 care providers). The recommendations varied in their specificity – from abstract guiding principles to 
447 detailed specific recommendations on necessary changes in practice and which tools may provide 
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448 actionable support. Multimorbidity guidelines more often provided generic guiding principles whereas 
449 those addressing polypharmacy tended to provide more specific recommendations and tools, but both 
450 remarkably neglected cognitive dysfunction. This is surprising for a frequent problem in this population, 
451 and one that is frequently underdiagnosed and has a major impact on health status and significant 
452 implications for self-management and interference with the health care system [49]. Furthermore, 
453 recommendations about pharmacologic treatment outweighed other types of recommendations (e.g. 
454 physical exercise) and no guideline specifically provided decision support for screening or diagnostic 
455 procedures. The impact of multimorbidity on diagnosis is not trivial as it can affect diagnostic accuracy 
456 and cause diagnostic delay with important implications for prognosis [50, 51].
457 The elicitation and consideration of patient preferences were considered as an essential part of the 
458 management of patients with multimorbidity and polypharmacy by all included guidelines.  Caution was 
459 recommended in the use of decision aids because they were mainly developed for single diseases. It is 
460 noteworthy, that only three guidelines involved patient representatives in the development process.
461
462 Barriers and facilitators to implementation of recommendations - models of care
463 A major barrier to implementation is that current health care models are based on the single disease 
464 paradigm, with the exceptions of certain settings (primary care) and specialties services (geriatrics, 
465 mental health). Guideline recommendations generally did not account for settings, with the exception of 
466 differentiated recommendations on instruments that can assist a clinician in determining patient 
467 functional capacity. For example, the comprehensive geriatric assessment has been shown to be 
468 effective in hospitals [38] but not in primary care [52]. Geriatricians and family physicians, while sharing a 
469 holistic approach, typically operate under different frameworks. Geriatricians are more often based in 
470 hospitals and provide care for the ‘geriatric patient’, while family physicians provide longitudinal care for 
471 unselected patients [53-55]. This has important implications in primary care, for example, in the 
472 organization of long-term follow-up and monitoring but also in the identification of patients with 
473 multimorbidity and polypharmacy who are at risk of developing negative health outcomes – that is to 
474 differentiate between the ‘fit and active’ and people in need for an intensified care approach [28]. 
475 Research is needed that supports reliable methods for ensuring that those most at risk of adverse events 
476 are identified and benefit from appropriate interventions.
477 The complexities associated with the management of multimorbidity and polypharmacy make it 
478 advisable to ensure the involvement of other health and social care professionals for patients with low 
Page 18 of 73Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
19
479 health literacy or a complex social background. Multi-professional care teams including social workers – 
480 and in certain countries, care coordinators– may facilitate the implementation of recommendations if a 
481 context-specific tailoring of the recommendations is warranted. 
482 Guidelines recommend clinicians to encourage self-management but the evidence for specific self-
483 management support programs on multimorbidity is lacking [56]. Further research is needed on 
484 interventions that support priority setting and strategies to reduce barriers to self-management. 
485
486 Communication with patients
487 All guidelines emphasized the importance of communication with patients and their carers about the 
488 patient’s needs, priorities and preferences for improving patient-centered health outcomes and 
489 minimizing the burden of care and overtreatment. Decision aids to support this communication process 
490 have been developed generally for single chronic diseases. Decisions about health care for patients with 
491 multimorbidity require a more individualized approach that considers outcomes across conditions, such 
492 as overall health related quality of life, functioning or symptom-free survival. 
493 Patient’s preferences for prioritized outcomes may shift over time [57] but also with regard to the 
494 alternatives [58, 59]. Repeated communication about the importance and prioritization of outcomes is 
495 therefore imperative. Instruments to communicate about prioritization and preferences with regard to 
496 outcomes have been developed, again mostly with a condition specific approach [60-62] and limited 
497 psychometric properties [61]. Individual goal setting and prioritization are core tasks in individualizing 
498 the care for patients with multimorbidity. Although interventions have been developed to support this 
499 collaborative process between patients and clinicians, the evidence supporting their effectiveness is still 
500 lacking [56]. Which components of these often multi-faceted interventions are most relevant is not clear 
501 [63]. 
502
503 Guidelines on multimorbidity vs. polypharmacy
504 Existing guidelines follow concepts on multimorbidity (diagnosis based) or polypharmacy (treatment 
505 based) but the issues raised are relevant to essentially the same patient population in clinical practice. 
506 Medication reviews for example, were at the core of the polypharmacy and multimorbidity guidelines 
507 and the review itself must take into consideration both patient’s conditions and treatments. The 
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508 separate production of guidelines addressing either multimorbidity or polypharmacy seems arbitrary and 
509 their combination would also relieve the burden – for developers and users. 
510
511 Limitations
512 The systematic guideline review method offers a transparent and comprehensive approach to the 
513 analysis of existing guidelines, but our in-depth text analysis may not be free from subjectivity with 
514 regard to the themes selected and presented in this review.
515
516 Concluding remarks
517 Our review identified eight comprehensive guidelines of good quality addressing older patients with 
518 multimorbidity or polypharmacy. The guideline recommendations covered a broad spectrum of aspects 
519 of clinical and self-management, beyond the realms of traditional disease-oriented guidelines. The 
520 recommendations varied in their specificity – from abstract guiding principles to detailed 
521 recommendations on necessary changes in practice and tools providing actionable support. The limited 
522 availability of reliable risk prediction models, feasible interventions of proven effectiveness and decision 
523 aids, as well as limited consensus on appropriate outcomes of care highlight major research deficits. An 
524 integrated approach to both multimorbidity and polypharmacy should be considered in future 
525 guidelines.
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709 Figure 1: Results of the search and selection process (flow chart)
710 Figure 2: Distribution of recommendations per topic and guideline
711
712 Table 1: Characteristics of included guidelines
713 Legend: *Used in 2/8 recommendations; †King's Fund definitions: Appropriate polypharmacy - 
714 'Prescribing for an individual for complex conditions or for multiple conditions in circumstances where 
715 medicines use has been optimized and where the medicines are prescribed according to best evidence'; 
716 Problematic polypharmacy - 'The prescribing of multiple [medicines] inappropriately, or where the 
717 intended benefit of the [medicines are] not realized'[33]; ‡Guiding principles for medicines optimization 
718 (the Royal Pharmaceutical Society): '(1) aim to understand the patient's experience, (2) evidence based 
719 choice of medicines, (3) ensure medicines use is as safe as possible, (4) make medicines optimization 
720 part of routine practice' [32]. Abbreviations: ADR – adverse drug reaction, GoR – grade of 
721 recommendation, LoE – level of evidence, MM – multimorbidity, PIM - potential inappropriate 
722 medication, PP – polypharmacy
723
724
725 Web-Supplement 1: search strategy and a complete list of web-sites visited
726 Web-Supplement 2: list of excluded guidelines with reason for exclusion
727 Web-Supplement 3: quality appraisal of included guidelines
728
Page 28 of 73Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Table 1: Characteristics of included guidelines 
Name, 
publication 
year 
Country of 
origin 
Target 
setting 
Underlying concept 
and definition 
Target population Outcomes addressed Underlying 
frameworks 
LoE 
/ 
GoR 
AGS 2012 
[26] 
U.S.A. Primary care, 
(secondary 
care) 
MM: multiple 
chronic conditions 
Older patients with MM Meaningful outcomes for 
older adults with MM 
(quality of life, physical 
function, independent living) 
and intermediate outcomes 
5 domains: Patient 
Preferences, 
Interpreting the 
Evidence, Prognosis, 
Clinical Feasibility, 
and Optimizing 
Therapies and Care 
Plans 
No 
DEGAM 
2017 [33] 
Germany Primary care MM: ≥3 chronic 
diseases 
Adult patients with MM (Patient-centred care) Meta-algorithm 
derived from N-of-1 
guideline approach 
Yes 
IMSS 2013 
[32] 
Mexico 'Primary 
care, 
(secondary 
care) 
PP: ≥4 medications Older people with PP Improvement in the quality 
of medical prescription in 
the elderly, preventing and 
detecting inappropriate 
prescription, reducing 
adverse drug events, 
n.a. Yes 
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Name, 
publication 
year 
Country of 
origin 
Target 
setting 
Underlying concept 
and definition 
Target population Outcomes addressed Underlying 
frameworks 
LoE 
/ 
GoR 
deterioration of patients' 
health and the unjustified 
expense of means 
LLGH & pmv 
& DEGAM 
2014 [31] 
Germany Primary care PP: ≥5 chronic 
prescriptions 
Adult patients with PP; excl.: 
palliative care 
PIM and related ADR, 
underuse and misuse, 
treatment burden 
Medication use 
process; 
Medication 
Appropriateness 
Index 
No 
NHG & 
NVKG & 
OMS 2012 
[27] 
Netherlands  Primary and 
secondary 
care 
PP: ≥5 chronic 
prescriptions 
Polypharmacy plus at least 
one risk factor: 
decreased kidney function; 
decreased cognitive function; 
increased fall risk; decreased 
compliance; living in an 
institution; unplanned 
hospital admission 
Optimizing medication use; 
decrease medication-related 
problems; decrease 
medication-related hospital 
admissions 
Systematic Tool to 
Reduce Inappropriate 
Prescribing (STRIP) 
No* 
NICE 2015a 
[28] 
UK Health and 
social care 
PP: King's Fund 
definition
†
 
People taking ≥1 medicines 
and their families and carers 
Up to 8 pre-specified 
outcomes per review 
question (e.g. clinical 
Guiding principles for 
medicines 
optimization (the 
Yes 
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Name, 
publication 
year 
Country of 
origin 
Target 
setting 
Underlying concept 
and definition 
Target population Outcomes addressed Underlying 
frameworks 
LoE 
/ 
GoR 
outcomes, medicine-related 
outcomes and problems, 
health and social care 
utilization, planned and 
unplanned health services 
contacts, health and social 
care related quality of life, 
for example long-term harm, 
disability) 
Royal Pharmaceutical 
Society)
‡
 
NICE 2015b 
[29] 
UK Health and 
social care 
MM: ≥1 long-term 
condition (lasting ≥1 
year and impacts on 
a person’s life) 
Older people with social care 
needs and multiple long-term 
conditions (including both 
physical and mental health 
conditions), and their carers. 
No pre-specified outcomes, 
full consideration of a wide 
range of outcomes as 
reported in studies 
n.a. No 
NICE 2016 
[30] 
UK Primary and 
secondary 
care, more 
specialized 
services 
MM: (1) the co-
existence of ≥2 long 
term conditions; (2) 
the combination of 
1 chronic disease 
Adults (≥18 yrs.) with 
multimorbidity; people with 
multiple conditions where 
these present significant 
problems to everyday 
To improve quality of life by 
promoting shared decisions 
based on what is important 
to each person in terms of 
treatments, health priorities, 
n. a. No 
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Name, 
publication 
year 
Country of 
origin 
Target 
setting 
Underlying concept 
and definition 
Target population Outcomes addressed Underlying 
frameworks 
LoE 
/ 
GoR 
with ≥1 other 
disease or bio 
psychosocial factor 
or somatic risk 
factor 
functioning or where the 
management of their care 
has become burdensome to 
the patient and/or involves a 
number of services working 
in an uncoordinated way. 
lifestyle and goals by means 
of by reducing treatment 
burden (polypharmacy and 
multiple appointments) and 
unplanned care 
 
Legend: *Used in 2/8 recommendaKons; †King's Fund definitions: Appropriate polypharmacy - 'Prescrib-ing for an individual for complex conditions or for 
multiple conditions in circumstances where medicines use has been optimized and where the medicines are prescribed according to best evidence'; Problem-
atic polypharmacy - 'The prescribing of multiple [medicines] inappropriately, or where the intended benefit of the [medicines are] not realized'[35]; ‡Guiding 
principles for medicines optimization (the Royal Pharmaceutical Society): '(1) aim to understand the patient's experience, (2) evidence based choice of 
medicines, (3) ensure medicines use is as safe as possible, (4) make medicines optimization part of routine practice' [34]. Abbreviations: ADR – adverse drug 
reaction, GoR – grade of recommen-dation, LoE – level of evidence, MM – multimorbidity, PIM - potential inappropriate medication, PP – polypharmacy 
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Figure 1: Results of the search and selection process (flow chart) 
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Table 1: List of databases and date of search 
Abbreviation Name, country and internet address Date 
Cochrane Cochrane Library 
http://onlinelibrary.wiley.com/cochranelibrary/search/ 
2018-02-20 
HSTAT Health Services/Technology Assessment Texts 
https://www.ncbi.nlm.nih.gov/books/NBK16710/ 
2018-02-20 
Medline Medline 
http://www.pubmed.com 
2018-02-20 
TRIP Trip Database 
www.tripdatabase.com 
2018-02-20 
 
Table 2: List of websites and organisations and dates of searches 
Abbreviation Name, country and internet address Date 
ACP American College of Physicians (USA) 
https://www.acponline.org/clinical-information/guidelines 
2018-02-10 
AGS American Geriatrics Society (USA) 
http://americangeriatrics.org 
2018-02-10 
AETMIS Agence d'Evaluation des Technologies et des Modes 
d'Intervention en Santé (Canada) 
https://www.cadth.ca/aetmis 
2018-02-10 
AHFMR Alberta Heritage Foundation for Medical Research (Canada) 
http://www.ahfmr.ab.ca/ 
2018-02-10 
AHRQ (AHCPR) Agency for Healthcare Research and Quality (USA) (formerly 
Agency for Health Care Policy and Research) 
http://www.ahrq.gov 
2018-02-12 
AkdÄ Arzneimittelkommission der deutschen Ärzteschaft 
www.akdae.de 
2018-03-29 
AMA Alberta Medical Association (Canada) 
http://www.albertadoctors.org/ 
2018-02-12 
AMDA American Medical Directors Association (The Society for post-
acute and long-term care medicine) 
www.amda.com 
2018-03-29 
ANZSGM Australian and New Zealand Society for Geriatric Medicine 
(Australia and New Zealand) 
http://www.anzsgm.org 
2018-02-12 
AWMF Arbeitsgemeinschaft der wissenschaftlichen medizinischen 
Fachgesellschaften 
http://www.awmf.org/awmf-online-das-portal-der-
wissenschaftlichen-medizin/awmf-aktuell.html  
2018-02-14 
ÄZQ Ärztliches Zentrum für Qualität in der Medizin 
http://www.aezq.de/  
2018-02-10 
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Abbreviation Name, country and internet address Date 
BÄK Bundesärztekammer 
www.baek.de 
2018-03-29 
BCC British Columbia Council 
www.bcguidelines.ca 
2018-03-29 
BGS British Society of Geriatrics (UK) 
http://www.bgs.org.uk 
2018-02-12 
BMA British Medical Association 
www.bma.org 
2018-03-29 
CADTH Canadian Agency for Drug and Technologies Assessment 
(Canada) 
http://www.cadth.ca 
2018-02-12 
CGS Canadian Geriatric Society (Canada) 
http://www.canadiangeriatrics.ca 
2018-02-12 
CDHSH Commonwealth Department of Human Services and Health 
(Australia) 
www.health.gov.au 
2018-02-12 
CEDIT Comité d’Evaluation et de Diffusion des Innovations 
Technologiques (France) 
http://cedit.aphp.fr/category/hta-2/ 
2018-02-12 
CMA Canadian Medical Association 
www.cma.ca 
2018-03-29 
CFP Canadian Family Physician (Canada) 
http://www.cfp.ca 
2018-02-12 
CTFPHC Canadian Task Force on Preventive Health Care (Canada) 
http://www.ctfphc.org/  
2018-02-12 
DEGAM Deutsche Gesellschaft für Allgemeinmedizin und 
Familienmedizin 
www.degam.de 
2018-02-14 
Deprescribing Deprescribing.org (Canada) 
http://www.deprescribing.org 
2018-02-13 
DGIM Deutsche Gesellschaft für Innere Medizin 
www.dgim.de 
2018-02-14 
DGK Deutsche Gesellschaft für Kardiologie 
www.dgk.org 
2018-02-22 
DIMDI Deutsches Institut für Dokumentation und Information 
www.dimdi.de 
2018-02-14 
Duodecim Leitlinienseite von The Finnish Medical Society Duodecim 
(Finland) 
https://www.duodecim.fi/english/duodecim/the-finnish-medical-
society-duodecim/ 
2018-02-13 
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Abbreviation Name, country and internet address Date 
Evidence.de Evidence.de 
www.evidence.de 
2018-03-29 
EUGMS European Union Geriatric Medicine Society (European Union) 
http://www.eugms.org/publications/resources.html 
2018-02-13 
GAIN Guidelines and Audit Implementation Network 
www.gain.org 
2018-03-29 
GIN Guideline International Network 
http://www.g-i-n.net 
2018-02-13 
GR Gezondheidsraad (Netherlands) 
http://www.gr.nl/ 
2018-02-13 
GSA The Gerontological Society of America (USA) 
http://geron.org 
2018-02-13 
GuiaSalud Biblioteca de Guías de Práctica Clínica del Sistema Nacional 
de Salud (Spain) 
http://www.guiasalud.es 
2018-02-13 
Guideline 
Central 
Guideline Central (USA) 
https://www.guidelinecentral.com/ 
2018-02-13 
HealthTeamWor
ks 
HealthTeamWorks 
www.healthteamworks.org 
2018-03-29 
HHS Unites States Department of Health and Human Services 
(USA) 
http://www.hhs.gov 
2018-02-13 
ICSI Institute for Clinical Systems Improvement (USA) 
http://www.icsi.org 
2018-02-13 
IMSANZ Internal Medicine Society of Australia and New Zealand 
(Australia and New Zealand) 
https://www.imsanz.org.au/ 
2018-02-13 
INAHTA International Network of Agencies for HTA (the former 
international organization for health technology assessment, 
today HTAI – Health Technology Assessment International) 
http://www.inahta.org 
2018-02-13 
ITA Institut für Technikfolgen-Abschätzung (Austria) 
https://www.oeaw.ac.at/itahome/ 
2018-02-13 
KBV Kassenärztliche Bundesvereinigung 
www.kbv.de  
2018-02-14 
MCRC Multiple Chronic Conditions Resource Center 
http://multiplechronicconditions.org/#MCC  
2018-04-16 
MJA Medical Journal of Australia 
www.mja.com.au 
2018-03-29 
MOH Ministry of Health Singapore 
www.moh.giv.sg  
2018-03-29 
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MSAC Medical Services Advisory Committee (Australia) 
http://www.msac.gov.au/ 
2018-02-13 
NGC National Guideline Clearinghouse (USA) 
https://www.guideline.gov/search?q=polypharmacy+OR+%22
multiple+drugs%22+OR+multimedication+OR+multimorbidity+
OR+%22multiple+conditions%22+OR+comorbidity&pageSize=
100&page=1 
2018-02-13 
NHMRC National Health Medical Research Council 
www.nhmrc.org.au 
2018-03-29 
NHS National Health Services (UK) 
http://www.nhs.uk 
2018-02-13 
NHS QIS NHS Quality Improvement Scotland (UK) 
http://www.nhshealthquality.org/nhsqis/nhsqis_sub_publication
s.jsp 
2018-02-13 
NICE National Institute for Clinical Excellence (UK) 
http://www.nice.org.uk/ 
2018-02-13 
NSW Health New South Wales H alth 
www.nih.gov 
2018-03-29 
NQMC National Quality Measures Clearinghouse (USA) 
http://www.qualitymeasures.ahrq.gov 
2018-02-13 
NZGG New Zealand Guideline Group (New Zealand) 
https://www.health.govt.nz/publications?f%5B0%5D=im_field_
publication_type%3A26 
2018-02-13 
NZHTA New Zealand Health Technology Assessment (New Zealand) 
http://www.otago.ac.nz/christchurch/research/nzhta/ 
2018-02-12 
REDETS Red Española de Agencia de Evaluación de Tecnologías 
(Spain) 
http://www.redets.msssi.gob.es/ 
2018-02-12 
SBU The Swedish Council on Technology Assessment in Health 
Care (Sweden) 
http://www.sbu.se/en/publications/ 
2018-02-12 
SEGG Sociedad Española de Geriatría y Gerontología (Spain) 
http://www.segg.es 
2018-02-12 
SEMI Sociedad Española de Medicina Interna (Spain) 
http://www.fesemi.org 
2018-02-12 
semFyC Sociedad Española de Medicina Familiar y Comunitaria 
(Spain) 
http://www.semfyc.es 
2018-02-12 
Sign Scottish Intercollegiate Guidelines Network 
www.sign.ac.uk 
2018-03-29 
SGIM Society of General Internal Medicine (USA) 
http://www.sgim.org 
2018-02-12 
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TA-SWISS Zentrum für Technikfolgenabschätzung (Switzerland),  
https://www.ta-swiss.ch/en/ 
2018-02-12 
TNO Nederlandse Organisatie voor toegepast-
natuurwetenschappelijk onderzozoek (Netherland) 
http://www.tno.nl/homepage.html 
2018-02-12 
USPSTF US Preventive Task Force (USA) 
https://www.uspreventiveservicestaskforce.org/ 
2018-02-12 
VATAP VA Technology Assessment Program, Department of Veterans 
Affairs (USA) 
https://www.healthquality.va.gov/ 
2018-02-12 
WHO World Health Organization  
 
2018-03-29 
ZonMw Netherlands Organization for Health Research and 
Development (Netherlands)  
http://www.zonmw.nl/index.asp?s=4535 
2018-02-12 
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Table 1: Quality appraisal of included guidelines
MiChe items
Guidelines
1. 
Identificati
on of key 
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dations and 
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sibleness
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n of the 
guideline’s 
target 
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and scope
3. 
Specificatio
n of the 
objectives 
and the 
target 
population
4. 
Independe
nce and 
potential 
conflicts of 
interests
5. 
Systematic 
search for 
evidence 
and 
selection 
criteria
6. 
Unambiguit
y of 
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dations
7. 
Different 
treatment 
options 
according 
to potential 
benefits, 
side effects 
and risks
8. 
Information 
on update 
procedures
Overall 
assessment
Recommen
dation for 
further use
AGS 2012 [26] 2 1 1 1 1 2 2 3 6 1
DEGAM 2017 [33] 1 1 1 2 2 1 2 1 6 1
IMSS 2013 [32] 1 1 1 1 1 2 1 3 5 2
LLGH & pmv & 
DEGAM 2014 [31]
1 1 1 1 1 1 1 1 7 1
NHG & NVKG & OMS 
2012 [27]
1 1 1 1 1 1 1 1 7 1
NICE 2015a [28] 1 1 1 1 1 1 1 1 7 1
NICE 2015b [29] 1 1 1 1 1 1 1 1 6 1
NICE 2016 [30] 1 1 1 1 1 2 1 2 6 1
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30 Abstract:
31 The complexity and heterogeneity of patients with multimorbidity and polypharmacy renders traditional 
32 disease-oriented guidelines often inadequate and complicates clinical decision making. To address this 
33 challenge, guidelines have been developed on multimorbidity or polypharmacy. To systematically 
34 analyze their recommendations, we conducted a systematic guideline review using the Ariadne 
35 principles for managing multimorbidity as analytical framework. The information synthesis included a 
36 multi-step consensus process involving 18 multi-disciplinary experts from seven countries. We included 
37 eight guidelines (four each on multimorbidity and polypharmacy) and extracted about 250 
38 recommendations. The guideline addressed (1) the identification of the target population (risk factors); 
39 (2) the assessment of interacting conditions and treatments: medical history, clinical and psychosocial 
40 assessment including physiological status and frailty, reviews of medication and encounters with 
41 healthcare providers highlighting informational continuity; (3) the need to incorporate patient 
42 preferences and goal setting: eliciting preferences and expectations, the process of shared decision 
43 making in relation to treatment options and the level of involvement of patients and carers; (4) 
44 individualized management: guiding principles on optimization of treatment benefits over possible 
45 harms, treatment communication and the information content of medication/care plans; (5) monitoring 
46 and follow-up: strategies in care planning, self-management and medication-related aspects, 
47 communication with patients including safety instructions and adherence, coordination of care regarding 
48 referral and discharge management, medication appropriateness and safety concerns. The spectrum of 
49 clinical and self-management issues varied from guiding principles to specific recommendations and 
50 tools providing actionable support. The limited availability of reliable risk prediction models, feasible 
51 interventions of proven effectiveness and decision aids, and limited consensus on appropriate outcomes 
52 of care highlight major research deficits. An integrated approach to both multimorbidity and 
53 polypharmacy should be considered in future guidelines.
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62 Background:
63 Family physicians care for patients with multiple conditions, known as multimorbidity [1] (see also 
64 review 1 [ref] in this issue), in up to 80% of their consultations [2], while in geriatrics this is the case for 
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66 in a number of ways. First, the potentially complex interlinked pathophysiological pathways underlying 
67 the conditions need to be taken into account in diagnosis and monitoring. Secondly, when developing 
68 care plans for these patients, the potential risks and benefits of interventions need to be taken into 
69 account both for each condition and across diseases. Furthermore, some concurrent conditions may not 
70 necessarily have a clinical impact but may complicate interpretation of symptom presentations. All this 
71 makes the process more difficult and the outcomes less certain [3]. 
72 Patients with multiple conditions commonly take multiple prescriptions (polypharmacy) [4], which 
73 further increase complexity. Firstly, by increasing the potential for interactions between diseases and 
74 treatments medication choice is less straightforward. Secondly, by increasing the possibility that 
75 additional medications will be prescribed to counteract side effects prescribing cascades may occur. 
76 Physicians involved in caring for these patients report that current decision support is inadequate to 
77 optimize benefits and minimize harms in these patients with complex needs [5].
78 More than a decade ago, attention was drawn to the fact that the application of individual disease-
79 oriented guidelines to patients with multimorbidity was not feasible and potentially harmful [6]. In 
80 addition to the potential harm from interactions between diseases and treatments, there is also an often 
81 unrecognized treatment burden [7, 8]. However, other studies indicate that adherence to clinical 
82 practice guidelines has the potential to improve outcomes for a range of chronic conditions including 
83 chronic heart failure and COPD, which commonly occur in people with multimorbidity [9-13]. 
84 Current approaches to support clinical decision making in multimorbidity and polypharmacy tend to 
85 adapt condition specific guidelines to take into account co-occurring problems; or to present principles 
86 on how to make a conscious use of disease oriented guidelines [14-16]. More recently, clinical practice 
87 guidelines for the management of multimorbidity and polypharmacy have been developed [17]. 
88 However, questions arise whether these guidelines provide relevant support for clinical decision making 
89 considering the vast heterogeneity of diseases, their potential combinations and varying degrees of 
90 disease severity in these patients.
91 We therefore aimed to identify and analyze available evidence-based clinical practice guidelines for 
92 multimorbidity or polypharmacy in order to investigate the clinical decision support they provide and the 
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93 key concepts they address. To facilitate the interpretation and actionability of the findings, we used the 
94 previously published Ariadne principles [15], which provide a framework to guide care delivery in 
95 patients with multimorbidity. At the core, the sharing of realistic treatment goals by physicians and 
96 patients results from i) an interaction assessment, i.e., the thorough assessment of diseases and 
97 treatments including their potential interactions, the patient’s clinical status, their context as well as a 
98 consideration of treatment burden; ii) the prioritization of health problems taking into account the 
99 patient’s preferences – his or her most and least desired outcomes; and iii) an individualized 
100 management plan which outlines the best options of care in diagnostics, treatment, and prevention to 
101 achieve the goals; iv) goal attainment is followed-up with a re-assessment in planned visits and v) the 
102 occurrence of new or changed conditions, such as an increase in severity, or a changed context may 
103 trigger a re-evaluation of the previous steps[15].
104
105
106 Methods:
107 We conducted a modified systematic guideline review [18] followed by a workshop-based consensus 
108 meeting with multidisciplinary experts from North America and Europe.
109
110 Literature Search and Selection
111 We conducted a systematic search for existing clinical practice guidelines in the electronic databases 
112 MEDLINE, The Cochrane Library, Health Services/Technology Assessment Texts (HSTAT), ‘Turning 
113 Research Into Practice’ (TRIP) and Guideline International Network (G-I-N) database, as well as in the 
114 National Guideline Clearinghouse combining controlled terms and free text words, such as comorbidity, 
115 multimorbidity, multiple conditions, polypharmacy, multiple drugs, multiple medications and older 
116 adults. We conducted the searches in February and March 2018, dated back to the database inception. 
117 In addition, we searched websites of guideline producing organizations including geriatric and primary 
118 care societies (the complete list is provided in Web-Supplement 1).
119 We included comprehensive guidelines or guideline-like documents on multimorbidity and 
120 polypharmacy, if they were “systematically developed statements to assist practitioner and patient 
121 decisions about appropriate health care for specific clinical circumstances" [19], if their purpose was "to 
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122 make explicit recommendations with a definite intent to influence what clinicians do" [20] and if they 
123 were endorsed by guideline producing organizations or physicians’ colleges. We accepted definitions of 
124 multimorbidity and polypharmacy used in individual guidelines and no language restriction was applied. 
125 We excluded disease-oriented guidelines (e.g., on osteoporosis management in elderly), guidelines with 
126 a narrow focus (e.g., on de-prescribing of potentially inappropriate medications in the elderly, using 
127 specific indicators such as Beers criteria [21]) or which did not report any methods of systematic 
128 development (a systematic literature search for at least some of the addressed questions had to be 
129 reported). Searches and selection of guidelines were conducted by two independent reviewers (AIGG 
130 and TSN).
131
132 Quality Appraisal
133 We (AIGG, MSB, JWB and TSN) appraised the quality of the guidelines using the MiChe Checklist [22, 23], 
134 which consists of eight specific questions (recommendations, audience, objectives, conflict of interest, 
135 systematic search, unambiguity, evaluation of benefits, and update) and two holistic items (overall 
136 assessment and recommendation for further use). Each specific question is answered as “Yes”, “No” or 
137 “To some extent”, the overall assessment is rated on a Likert scale ranging from “1”=very poor to 
138 “7”=very good, and the recommendation is rated with “Yes”, “Yes, with certain reservations”, and “No”.
139
140 Data extraction
141 We (AIGG, CM, JWB, MSB, TSN) extracted data from the guidelines according to a pre-defined 
142 framework based on the Ariadne principles [15], which encompassed recommendations on (i) 
143 interaction assessment, (ii) prioritization of patient’s preferences and agreement on shared treatment 
144 goals, (iii) individualized management of patients to achieve these goals and (iv) monitoring and follow-
145 up of goal attainment. To fit the aim of the framework analysis, (v) (‘trigger events’ to (re)start the 
146 Ariadne principles) was reframed as methods for ’identification of the target population’. 
147 Additional information on each guideline was extracted: the source, the year of publication, the country 
148 of origin, underlying concepts including definitions of multimorbidity and polypharmacy, the target 
149 setting, the target population and patient-related outcomes. For each topic of the a priori defined 
150 Ariadne framework, we (AIGG, CM, JWB, MSB, TSN) extracted the data into evidence tables using a 
151 standardized format, which included recommendation(s), level of evidence (LoE) and grade of 
152 recommendation (GoR) as provided in the guideline. When recommendations addressed more than one 
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153 domain of the framework, we (CM, JWB) agreed upon the domain that best matched the 
154 recommendation to avoid duplicates.
155
156 Analysis 
157 The numbers of recommendations per topic and per guideline were described. We (AIGG, CM, JWB, 
158 SMS, TSN) conducted a thematic analysis, assigned categories and aggregated the recommendations as 
159 outlined above using the Ariadne framework.
160
161 Expert consensus process
162 We discussed the results of the thematic synthesis at a two-day meeting in May 2018. This meeting 
163 included a symposium, in which the background to the topic was elucidated and a workshop with 18 
164 invited multidisciplinary experts – some of them with more than one area of expertise: geriatrics (7), 
165 primary care (6), public health and health services research (5), epidemiology (4) and 
166 pharmacy/pharmacology (2) from seven countries (Sweden (5), UK (4), USA (3), Italy and the Netherlands 
167 (2), Germany and Ireland (1); see Web-Supplement 2). The group discussion was audio-recorded and 
168 transcribed and served as triangulation of the thematic analysis. The results of the guideline review and 
169 the group discussion were agreed upon and synthetized by all authors.
170
171
172 Results:
173 In total, we included eight guidelines, four on multimorbidity and four on polypharmacy [24-31] (Figure 
174 1; the list of excluded guidelines with reasons for exclusion is provided in Web-Supplement 23). Three 
175 guidelines were developed in the UK, two in Germany and one each in the US, the Netherlands and 
176 Mexico (Table 1 [32, 33]). Four guidelines were of very good quality, the remaining had minor 
177 shortcomings - mainly due to a limited reporting quality, including two which did not report on update 
178 procedures and therefore scored lowest in that domain (for details of the quality appraisal see Web-
179 Supplement 34).
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180 In total, we extracted 246 recommendations (median: 27 recommendations per guideline (IQR: 13 to 52, 
181 range: 7-57)). The most common recommendations addressed the need for a thorough assessment of 
182 interactions and individualized management of patients (n=69 recommendations each), followed by 
183 identifying patient’s preferences and goal setting (n=50), monitoring and follow-up (n=32), and 
184 identification of the target population (n=26) (Figure 2). Some of the recommendations were not specific 
185 to a single domain, for example, recommendations on individualized management also incorporated 
186 elements of monitoring and follow up.
187
188 [About here: Figure 1: Results of the search and selection process (flow chart)]
189
190 [About here: Table 1: Characteristics of included guidelines]
191
192 [About here: Figure 2: Distribution of recommendations per topic and guideline]
193
194 Identification of the target population
195 In one guideline, a systematic search for existing risk predicting models revealed many models for 
196 patients with multimorbidity but not for patients with polypharmacy [28]. This guideline recommended 
197 the identification of adults with multimorbidity at risk of adverse events (e.g., unplanned hospital 
198 admission or admission to a care home) using prognostic models – either opportunistically during 
199 routine care or proactively using the electronic medical record (EMR) [28]. Five guidelines provided 
200 information about risk factors for negative health outcomes  covering different dimensions, such as 
201 condition-, medication-, adherence-related, and risks related to social context and health care utilization 
202 [25, 26, 28-30]. Condition-related risk factors included the presence of certain chronic diseases such as 
203 depression, dementia or cognitive decline, combinations of chronic mental and physical diseases such as 
204 diabetes and schizophrenia, the presence of conditions or events such as frailty, falls, non-specific 
205 symptoms and a worsening of health [25, 28-30]. Medication-related risks referred to drugs with a 
206 narrow therapeutic range, high potential for drug-drug interactions, the need for constant monitoring, 
207 psychotropic drugs and where patients received a suboptimal benefit from pharmaceutical treatment 
208 [26, 29]. Patients with non-adherence, difficulties managing their treatment regimen due to a high 
209 treatment burden or administration problems were also regarded as being at risk [25, 28, 29]. Social risk 
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210 factors included problems managing day-to-day activities, not living independently, limited ability to 
211 understand treatment recommendations (e.g., language problems and health literacy ), advanced age 
212 and limited access to health care [25, 28-30]. The involvement of multiple and uncoordinated health care 
213 professionals and low uptake of care plans was noted to increase unplanned hospital admissions and 
214 emergency care [25, 28, 29].
215
216 Interaction assessment
217 According to the Ariadne Principles the interaction assessment should be conducted as a thorough 
218 assessment of diseases (including severity and impact on quality of life and functioning) and treatments 
219 (including potential interactions, adverse drug reactions, under-use and adherence), and of the clinical 
220 status and psychosocial context of the patient [15]. Seven guidelines addressed this principle, covering 
221 the medical history, a clinical and psychosocial assessment, a medication review and consideration of 
222 previous health services utilization [25-31]. Regarding the medical history, the documentation of all 
223 known diagnoses and conditions as well as existing laboratory test results and medication-related 
224 problems in the electronic medical record was recommended [25, 29]. One guideline [25] recommended 
225 the use of a structured questionnaire [34] about medication use, problems, experiences, worries and 
226 expectations. The clinical assessment included identification of a wide range of health problems as well 
227 as an assessment of physiological status and frailty [27, 28]. Recommendations on a medication review 
228 were at the core of the included polypharmacy guidelines, but were also addressed in the multimorbidity 
229 guidelines. One of them stressed the importance of informational continuity, in order to explore 
230 encounters with other physicians or health care professionals and changes in management over time 
231 [29] (Textbox 1).
232
233 [About here: 
234 Textbox 1: Key recommendations on interaction assessment
235 Guiding principles
236  Assess diseases, health problems, clinical and functional status, pharmacological and non-
237 pharmacological treatment including potential interactions between diseases and treatments as well 
238 as the burden for the patient and take into account his/her psychosocial context [25-31].
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239  Involve patients and their family members or carers, where appropriate, in the assessment process, 
240 and clarify and resolve misconceptions [26, 31].
241  Explore patient’s contacts with other health care professionals and any related changes in 
242 management and consider using information technology support and a multidisciplinary team-based 
243 approach [26, 28, 29, 31].
244 Specific recommendations on clinical management
245  Clinical assessment: Assess the management of health problems such as chronic pain, depression 
246 and anxiety, the presence of incontinence, the physiological and functional status and whether there 
247 are nutritional and hydration requirements [27, 28].
248  Medication review: Evaluate the risk-benefit of each drug, its possible interactions and adverse 
249 effects, adherence to treatment and unmet needs and be aware of possible prescribing cascades [29, 
250 30]. Assess the use of prescriptions, over-the-counter and food supplements or medicinal herbs and 
251 the actual implementation of a medication plan [29, 30]. Undertake a medication review regularly 
252 once a year; more often if needed, for example in relation to hospital stays: on admission, transfers 
253 between wards and at discharge [27, 29]. Use multiple methods such as health record reviews, 
254 patient surveys during consultations in practice or home visits and direct observation of medicines 
255 administration [26-29].
256 Specific recommendations on self-management support†
257  Establish disease and treatment burden, its effect on day-to-day life including mental health, general 
258 wellbeing and quality of life [28]. Establish additional burden arising from caring responsibilities [27]. 
259 These features need to be incorporated when considering patients’ capacity and the supports 
260 needed for self-management of long-term conditions and treatments [27].
261 Toolbox
262 Clinical assessment
263  Instruments determining patient capacity and vulnerability to interactions, such as gait speed, self-
264 reported health status, the PRISMA-7 questionnaire [35] (primary care), the 'Timed Up and Go' test 
265 [36], the Physical Activity Scale for the Elderly [37] (hospital outpatients) and Comprehensive 
266 Geriatric Assessment, CGA [38] (hospitals).
267 Medication assessment
268  Instruments based on implicit criteria, such as MAI (Medication Appropriateness Index) [39], ACOVE 
269 (Assessing Care of Vulnerable Elders) [40], and the STRIP method (Systematic Tool to Reduce 
270 Inappropriate Prescribing) [28].
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271  Instruments based on explicit criteria, such as the STOPP (Screening Tool of Older Person's 
272 Prescriptions), START (Screening Tool to Alert doctors to Right Treatment) [41, 42], PIM lists 
273 (Potentially Inappropriate Medications, e.g., Beers criteria, EU-PIM list) [21, 43], FORTA (Fit for The 
274 Aged) [44-46], QT drug lists [47], databases on interactions, dosage adaption according to renal 
275 function and fall risk increasing drugs.
276
277 †We defined self-management support as the care and encouragement provided to people with chronic 
278 conditions and their families to help them understand their central role in managing their illness, make 
279 informed decision about care and engage in healthy behaviors (MacColl Center [50]).
280 End of Textbox 1]
281
282 Patient’s preferences, prioritization and goal setting
283 All but one of the guidelines provided recommendations on eliciting patient preferences and 
284 expectations, including guidance on the level of involvement of patients and carers. The 
285 recommendations also focus on the process of shared decision making in relation to treatment options 
286 and the way they are communicated [24-29, 31]. Two guidelines provided specific recommendations 
287 regarding decision aids as tools to support shared decision-making [26, 28]. Additionally, one guideline 
288 referred to the need for specific skills and expertise in the use of patient decision aids [26] (Textbox 2).
289
290 [About here: 
291 Textbox 2: Key recommendations on eliciting patient’s preferences and sharing realistic treatment goals.
292 Guiding principles
293  Patients should be encouraged to express their personal values, aims and priorities. The attitude of 
294 the patient regarding the treatment and its potential benefit has to be explored [26, 28, 31]. This 
295 includes addressing medical, psychological, emotional, social, personal, sexual, spiritual, cultural 
296 needs, vision, hearing and communication needs, environmental care needs and palliative and end 
297 of life care needs [24, 27].
298 Specific recommendations on clinical management
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299  Discuss with the person the purpose of the approach to care, for example, to improve quality of life 
300 and function. This might include reducing treatment burden and optimizing care and support by 
301 identifying possible improvements in medication and reducing inappropriate or medication with 
302 negative effect [28].
303  The process of eliciting patient preferences requires several steps: 1) recognize when the patient 
304 with multimorbidity is facing a “preference sensitive” decision; 2) ensure patients with 
305 multimorbidity are adequately informed about the expected benefits and harms and 3) elicit patient 
306 preferences only after the individual with multimorbidity is sufficiently informed [24].
307  Explore patient’s expectations and objectives about treatments before prescribing [29].
308  Find out what level of involvement in decision-making the person would like and avoid making 
309 assumptions about this [26].
310  Use the best available evidence when making decisions with or for individuals, together with the 
311 clinical expertise and the person’s values and preferences [26].
312 Specific recommendations on self-management support
313  Encourage patients with multimorbidity to clarify what is important to them, including their personal 
314 goals, values and priorities [28].
315 Toolbox
316  Use a patient decision aid to help them make a preference-sensitive decision that involves trade-offs 
317 between benefits and harms, if available in high quality and appropriate in the context of the 
318 consultation as a whole [26].
319 End of Textbox 2]
320
321 Individualized management
322 All guidelines provided recommendations on this topic. Guiding principles referred to the optimization of 
323 treatment benefits over possible harms in pharmaceutical and non-pharmaceutical interventions. They 
324 also referred to information that should be included in medication plans – and, in wider care plans, 
325 including social and tele-healthcare [24, 26-30]. Recommendations on treatment communication (with 
326 or without direct consideration of self-management support) was a strong focus in four guidelines [26-
327 29] and the coordination of care was addressed in more than half of guidelines [24, 26-29, 31]. Self-
328 management support was addressed indirectly in relation to individualized management in half of the 
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329 guidelines [26-29]. The guidelines which addressed this issue focused primarily on self-management 
330 support for medicines management and support with care coordination (Textbox 3).
331
332 [About here: 
333 Textbox 3: Key recommendations on individualized management
334 Guiding principles
335  Use strategies for choosing therapies that optimize benefit, minimize harm, and enhance quality of 
336 life for patients with multimorbidity and consider treatment burden, complexity and feasibility [24, 
337 28].
338  Consider the applicability and quality of evidence such as study population, study duration, benefits 
339 in terms of absolute risk reduction and time horizon. Studies in younger patients without 
340 multimorbidity and polypharmacy and with short follow-up times and relative risk reduction may 
341 overestimate benefits and underestimate harms, and time horizon to benefit may be too late to 
342 achieve relevant treatment effects in older patients with multimorbidity and polypharmacy [24, 28, 
343 30].
344  In deprescribing medication(s), follow a systematic approach including identification and 
345 prioritization of medicines to be discontinued, stopping one at a time and consideration of tapering 
346 dosage rather than stopping, and planning and communicating with patients (and caregivers, if 
347 necessary) [29].
348  Ensure care plans are tailored to each person, giving them choice and control and recognizing the 
349 inter-related nature of multiple long-term conditions [27].
350  Health professionals involved in the treatment of patients with multimorbidity should share relevant 
351 information about the person and their medicines – in particular when patients are transferred to 
352 another care setting [27, 31].
353 Specific recommendations on clinical management
354  Be aware that the management of risk factors for future disease can be a major treatment burden 
355 for people with multimorbidity and should be carefully considered when optimizing care [28].
356  When prescribing medications such as statins and bisphosphonates, be aware that they may only 
357 provide benefit to elderly patients who have estimated survival greater than five years [30].
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358  The selection of a primary pharmacy is recommended to support the coordination of self-
359 administered drugs with regard to dosage instructions and overall medication regimens, particularly 
360 when there are multiple prescribers [29].
361  Ensure there is community based multidisciplinary support for patients with multimorbidity with 
362 social care needs which might include, for example, a physiotherapist or occupational therapist, a 
363 mental health social worker or psychiatrist, and community based services [27].
364 Specific recommendations on self-management support
365  Consider using an individualized patient-held medication plan that should include information on 
366 drugs and specific instruction for usage; if dosage is 'as needed', exact information about indication 
367 and individual dosage must be provided (single dose, interval and maximal daily dosage); in short-
368 term prescriptions, the prospective end date should be specified and information about medication 
369 history and reduced renal function should be included when indicated [29].
370  Develop care plans that address ongoing medical and social care needs for individual patients that 
371 focus on enhancing social connectedness and community involvement and also ensuring that carers’ 
372 needs are taken into consideration and that these care plans do not add to treatment burden [26-
373 28].
374  Ensure ongoing and adequate communication, in particular around medicines and wider care plans 
375 with identification of perceived benefits and ensuring patient involvement in the process [26-28].
376  Consider with the person whether there are tele-healthcare options that may support them to make 
377 informed choices to help them manage their conditions, as well as other potential benefits, risks and 
378 costs [27].
379  Consider the use of named care coordinators who can agree a course of action with patients and 
380 their carers if these needs cannot be addressed by existing health and social care professionals. This 
381 may be particularly important at times of transition, for example when considering moving to a care 
382 home [27].
383 Toolbox
384  Computerized decision support systems (CDSS) that support decision-making and prescribing but do 
385 not replace clinical judgment; and options for tele-healthcare [26, 27].
386 End of Textbox 3]
387
388 Monitoring and follow-up
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389 In five guidelines, aspects of follow-up and monitoring of treatment effects as well as goal attainment 
390 were addressed [25-29]. Recommendations covered strategies in care planning, self-management and 
391 medication-related aspects, the communication with patients including patient information and safety 
392 instructions as well as adherence, the coordination of care regarding medication appropriateness and 
393 safety concerns, possible collaboration with pharmacies, the involvement of care coordinators, referrals 
394 and discharge management [25-29]. Additionally, organizational or health care professionals’ 
395 responsibilities with regard to follow-up of medication-related aspects and the specific conditions in care 
396 homes were addressed in two guidelines [26, 27] (Textbox 4).
397
398 [About here:
399 Textbox 4: Key recommendations on monitoring and follow-up
400 Guiding principles
401  Review and update medication / care plans regularly to recognize and record changes in needs [25-
402 29].
403 Specific recommendations on clinical management
404  Monitor treatment effects and clinical parameters, as well as side effects at follow-up appointments. 
405 Check for non-specific symptoms as potential indicators of complications resulting from treatment 
406 changes such as dry mouth, weakness / exhaustion / fatigue, drowsiness, reduced alertness, sleep 
407 disturbances, motor disorders, tremors, falls; constipation, diarrhea, incontinence, loss of appetite, 
408 nausea; skin rashes, itching; depression or lack of interest in usual activities, confusion (temporary or 
409 chronic), hallucinations, fear and agitation, vertigo, tinnitus and control clinical parameters (e.g., 
410 health examination, if necessary lab tests, ECG). Consider increasing the frequency of follow-up visits 
411 following treatment changes [29].
412  Monitor treatment after discharge: due to the (usually) short duration of a hospital stay, newly 
413 introduced medications may not have reached steady state at discharge, because inpatient care is 
414 frequently shorter than 4 to 5 half-lives of prescribed drugs. Effectiveness and side effects cannot 
415 necessarily be properly assessed in hospital [29].
416  Monitor ongoing treatment including demonstrations of medication administration (e.g., inhalers) 
417 and effective forms of self-monitoring [29].
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418  Consider continuing to offer information and support to people and their carers, even if they have 
419 declined this previously, recognizing that long-term conditions can be changeable or progressive, 
420 and people's information needs may change [26].
421 Specific recommendations on self-management support
422  Review the self-management plan to ensure the person does not have problems using it [26].
423  Health and social care providers should explain to patients, and their family members or carers 
424 where appropriate, how to identify and report medicines-related patient safety incidents that arise 
425 during follow-up periods [26].
426  Self-management plans could include specific arrangements about follow-up to review the decisions 
427 made [28].
428 End of Textbox 4]
429
430
431 Discussion
432 Summary of included guidelines
433 Our review identified eight comprehensive guidelines addressing older patients with multimorbidity or 
434 polypharmacy. Many guidelines had to be excluded, mainly due to a lack of reporting of systematic 
435 search strategies. The vast majority of the included guidelines were of good quality according to the 
436 MiChe checklist [22, 23]. Interestingly, only three out of eight guidelines used levels of evidence and 
437 grades of recommendations, despite the recognition of their importance [48]. This may reflect the fact 
438 that evidence for effective interventions in this population is scarce and that expert consensus may often 
439 represent the best available evidence. However, this has also been the case for disease-specific 
440 guidelines. For example in chronic heart failure, a review found that about half of the guideline 
441 recommendations were consensus based [18]. There is a clear need to prioritize research to generate 
442 evidence for effective interventions in ‘real world-patients’.
443 The recommendations included in the guidelines covered a broad spectrum of aspects related to clinical 
444 management and self-management and included recommendations beyond traditional realms of clinical 
445 guidelines (e.g., regarding structural requirements of organizations, knowledge and skills of different 
446 care providers). The recommendations varied in their specificity – from abstract guiding principles to 
447 detailed specific recommendations on necessary changes in practice and which tools may provide 
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448 actionable support. Multimorbidity guidelines more often provided generic guiding principles whereas 
449 those addressing polypharmacy tended to provide more specific recommendations and tools, but both 
450 remarkably neglected cognitive dysfunction. This is surprising for a frequent problem in this population, 
451 and one that is frequently underdiagnosed and has a major impact on health status and significant 
452 implications for self-management and interference with the health care system [49]. Furthermore, 
453 recommendations about pharmacologic treatment outweighed other types of recommendations (e.g. 
454 physical exercise) and no guideline specifically provided decision support for screening or diagnostic 
455 procedures. The impact of multimorbidity on diagnosis is not trivial as it can affect diagnostic accuracy 
456 and cause diagnostic delay with important implications for prognosis [50, 51].
457 The elicitation and consideration of patient preferences were considered as an essential part of the 
458 management of patients with multimorbidity and polypharmacy by all included guidelines.  Caution was 
459 recommended in the use of decision aids because they were mainly developed for single diseases. It is 
460 noteworthy, that only three guidelines involved patient representatives in the development process.
461
462 Barriers and facilitators to implementation of recommendations - models of care
463 A major barrier to implementation is that current health care models are based on the single disease 
464 paradigm, with the exceptions of certain settings (primary care) and specialties services (geriatrics, 
465 mental health) (see review no. 3 [ref] in this issue). Guideline recommendations generally did not 
466 account for settings, with the exception of differentiated recommendations on instruments that can 
467 assist a clinician in determining patient functional capacity. For example, the comprehensive geriatric 
468 assessment has been shown to be effective in hospitals [38] but not in primary care [52]. Geriatricians 
469 and family physicians, while sharing a holistic approach, typically operate under different frameworks. 
470 Geriatricians are more often based in hospitals and provide care for the ‘geriatric patient’, while family 
471 physicians provide longitudinal care for unselected patients [53-55]. This has important implications in 
472 primary care, for example, in the organization of long-term follow-up and monitoring but also in the 
473 identification of patients with multimorbidity and polypharmacy who are at risk of developing negative 
474 health outcomes – that is to differentiate between the ‘fit and active’ and people in need for an 
475 intensified care approach [28]. Research is needed that supports reliable methods for ensuring that 
476 those most at risk of adverse events are identified and benefit from appropriate interventions.
477 The complexities associated with the management of multimorbidity and polypharmacy make it 
478 advisable to ensure the involvement of other health and social care professionals for patients with low 
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479 health literacy or a complex social background. Multi-professional care teams including social workers – 
480 and in certain countries, care coordinators– may facilitate the implementation of recommendations if a 
481 context-specific tailoring of the recommendations is warranted. 
482 Guidelines recommend clinicians to encourage self-management but the evidence for specific self-
483 management support programs on multimorbidity is lacking [56]. Further research is needed on 
484 interventions that support priority setting and strategies to reduce barriers to self-management. 
485
486 Communication with patients
487 All guidelines emphasized the importance of communication with patients and their carers about the 
488 patient’s needs, priorities and preferences for improving patient-centered health outcomes and 
489 minimizing the burden of care and overtreatment. Decision aids to support this communication process 
490 have been developed generally for single chronic diseases. Decisions about health care for patients with 
491 multimorbidity require a more individualized approach that considers outcomes across conditions, such 
492 as overall health related quality of life, functioning or symptom-free survival. 
493 Patient’s preferences for prioritized outcomes may shift over time [57] but also with regard to the 
494 alternatives [58, 59]. Repeated communication about the importance and prioritization of outcomes is 
495 therefore imperative. Instruments to communicate about prioritization and preferences with regard to 
496 outcomes have been developed, again mostly with a condition specific approach [60-62] and limited 
497 psychometric properties [61]. Individual goal setting and prioritization are core tasks in individualizing 
498 the care for patients with multimorbidity. Although interventions have been developed to support this 
499 collaborative process between patients and clinicians, the evidence supporting their effectiveness is still 
500 lacking [56]. Which components of these often multi-faceted interventions are most relevant is not clear 
501 [63]. 
502
503 Guidelines on multimorbidity vs. polypharmacy
504 Existing guidelines follow concepts on multimorbidity (diagnosis based) or polypharmacy (treatment 
505 based) but the issues raised are relevant to essentially the same patient population in clinical practice. 
506 Medication reviews for example, were at the core of the polypharmacy and multimorbidity guidelines 
507 and the review itself must take into consideration both patient’s conditions and treatments. The 
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508 separate production of guidelines addressing either multimorbidity or polypharmacy seems arbitrary and 
509 their combination would also relieve the burden – for developers and users. 
510
511 Limitations
512 The systematic guideline review method offers a transparent and comprehensive approach to the 
513 analysis of existing guidelines, but our in-depth text analysis may not be free from subjectivity with 
514 regard to the themes selected and presented in this review.
515
516 Concluding remarks
517 Our review identified eight comprehensive guidelines of good quality addressing older patients with 
518 multimorbidity or polypharmacy. The guideline recommendations covered a broad spectrum of aspects 
519 of clinical and self-management, beyond the realms of traditional disease-oriented guidelines. The 
520 recommendations varied in their specificity – from abstract guiding principles to detailed 
521 recommendations on necessary changes in practice and tools providing actionable support. The limited 
522 availability of reliable risk prediction models, feasible interventions of proven effectiveness and decision 
523 aids, as well as limited consensus on appropriate outcomes of care highlight major research deficits. An 
524 integrated approach to both multimorbidity and polypharmacy should be considered in future 
525 guidelines.
526
527 Conflict of interest statement
528 The authors have nothing to disclose.
529
530 Authors’ contributions:
531 Drs. CM, JMV and JWB designed the concept and the program for the workshop and agreed upon with all 
532 authors. Drs. CM and JWB had full access to all of the data in the study, and took responsibility for the 
533 integrity of the data and the accuracy of the data analysis. Drs. AIGG, CM, JWB, MSB and TSN extracted 
534 the data and assigned them to the Ariadne framework. Drs. AIGG, CM, JWB, SMS, MSB and TSN drafted 
535 the information synthesis. Drs. CM, JWB, SMS, MET, KJ and JMV led the workshop. Drs. CM, JWB, JMV, 
Page 65 of 73 Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
21
536 SMS, AIGG, and MC drafted the first manuscript and all authors substantially contributed to the 
537 conception, acquisition, analysis and interpretation of data, revised the manuscript critically for 
538 important intellectual content, and finally approved it to be published.
539
540 Acknowledgments
541 The authors would like to thank Cynthia M. Boyd, Maria Eriksdotter, Luigi Ferrucci, Laura Fratiglioni, 
542 Amaia Calderón Larrañaga, Alessandra Marengoni, Stewart W. Mercer, Ellen Nolte, Graziano Onder, 
543 Mieke Rijken, Martin Roland and Davide L. Vetrano for their active contribution to the fruitful discussion 
544 of the workshop.
545
546 Funding
547 (A uniform statement about the funders and editorial independence will be provided in the three 
548 reviews.)
549 Funding was provided by the Journal of Internal Medicine and Karolinska Institutet Strategic Research 
550 Area in Epidemiology (SfoEpi). The funder had no role in study design, data collection and analysis, 
551 decision to publish or preparation of the manuscript. The views expressed in this paper are those of the 
552 authors and not necessarily those of the funders.
553
554 References
555
556 1 van den Akker M, Buntinx F, Knottnerus J. Comorbidity or multimorbidity: what's in a name. A 
557 review of literature. Eur J Gen Pract 1996; 2: 65-70.
558 2 Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA. Epidemiology and impact of 
559 multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract 2011; 61: e12-e21.
560 3 Salisbury C, Procter S, Stewart K, et al. The content of general practice consultations: cross-
561 sectional study based on video recordings. Br J Gen Pract 2013; 63: 751-9.
Page 66 of 73Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
22
562 4 Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and 
563 polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med 2011; 22: 
564 597-602.
565 5 Sinnott C, McHugh S, Browne J, Bradley C. GPs' perspectives on the management of patients with 
566 multimorbidity: systematic review and synthesis of qualitative research. BMJ Open 2013; 3: e003610.
567 6 Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of 
568 care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 
569 2005; 294: 716-24.
570 7 May C, Montori VM, Mair FS. We need minimally disruptive medicine. BMJ 2009; 339: b2803.
571 8 Montori VM, Brito J, Murad M. The optimal practice of evidence-based medicine: Incorporating 
572 patient preferences in practice guidelines. JAMA 2013; 310: 2503-04.
573 9 Dennis SM, Zwar N, Griffiths R, Roland M, Hasan I, Powell Davies G, Harris M. Chronic disease 
574 management in primary care: from evidence to policy. Med J Aust 2008; 188: S53-6.
575 10 Komajda M, Lapuerta P, Hermans N, et al. Adherence to guidelines is a predictor of outcome in 
576 chronic heart failure: the MAHLER survey. Eur Heart J 2005; 26: 1653-9.
577 11 Peytremann-Bridevaux I, Arditi C, Gex G, Bridevaux P-O, Burnand B. Chronic disease 
578 management programmes for adults with asthma. Cochrane Database of Systematic Reviews 2015: 
579 CD007988.
580 12 Tinetti ME, McAvay G, Trentalange M, Cohen AB, Allore HG. Association between guideline 
581 recommended drugs and death in older adults with multiple chronic conditions: population based cohort 
582 study. BMJ 2015; 351: h4984.
583 13 Weingarten SR, Henning JM, Badamgarav E, Knight K, Hasselblad V, Jr AG, Ofman JJ. 
584 Interventions used in disease management programmes for patients with chronic illnesswhich ones 
585 work? Meta-analysis of published reports. BMJ 2002; 325: 925.
586 14 Guthrie B, Payne K, Alderson P, McMurdo ME, Mercer SW. Adapting clinical guidelines to take 
587 account of multimorbidity. BMJ 2012; 345: e6341.
Page 67 of 73 Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
23
588 15 Muth C, van den Akker M, Blom JW, et al. The Ariadne principles: how to handle multimorbidity 
589 in primary care consultations. BMC Med 2014; 12: 223.
590 16 Wallace E, Salisbury C, Guthrie B, Lewis C, Fahey T, Smith SM. Managing patients with 
591 multimorbidity in primary care. BMJ 2015; 350: h176.
592 17 Farmer C, Fenu E, O'Flynn N, Guthrie B. Clinical assessment and management of multimorbidity: 
593 summary of NICE guidance. BMJ 2016; 354: i4843.
594 18 Muth C, Gensichen J, Beyer M, Hutchinson A, Gerlach FM. The systematic guideline review: 
595 method, rationale, and test on chronic heart failure. BMC Health Serv Res 2009; 9: 74.
596 19 Field MJ, Lohr KN, (eds.). Institute of Medicine. Clinical Practice Guidelines: Directions for a New 
597 Program. Washington, DC: National Academy Press. 1990.
598 20 Hayward RSA, Wilson MC, Tunis SR, Bass EB, Guyatt G. Users' Guides to the Medical Literature. 
599 VIII. How to use Clinical Guidelines. A. Are the recommendations valid? JAMA 1995; 274: 570-4.
600 21 American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate 
601 Medication Use in Older Adults. J Am Geriatr Soc 2015; 63: 2227-46.
602 22 Semlitsch T, Jeitler K, Kopp IB, Siebenhofer A. [Development of a workable mini checklist to 
603 assess guideline quality]. Z Evid Fortbild Qual Gesundhwes 2014; 108: 299-312.
604 23 Semlitsch T, Blank WA, Kopp IB, Siering U, Siebenhofer A. Evaluating Guidelines: A Review of Key 
605 Quality Criteria. Dtsch Arztebl Int 2015; 112: 471-8.
606 24 AGS. Guiding principles for the care of older adults with multimorbidity: an approach for 
607 clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J 
608 Am Geriatr Soc 2012; 60: E1-E25.
609 25 NHG. Multidisciplinaire Richtlijn Polyfarmacie bij ouderen.  Available at: 
610 https://www.nhg.org/sites/default/files/content/nhg_org/uploads/polyfarmacie_bij_ouderen.pdf. Last 
611 access: 10 Jun 2018.
Page 68 of 73Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
24
612 26 NICE. Medicines optimisation: the safe and effective use of medicines to enable the best possible 
613 outcomes.  Available at: https://www.nice.org.uk/guidance/ng5/evidence/full-guideline-pdf-6775454. 
614 Last access: 10 Jun 2018.
615 27 NICE. Older people with social care needs and multiple long-term conditions.  Available at: 
616 https://www.nice.org.uk/guidance/ng22/evidence/full-guideline-pdf-552742669. Last access: 10 Jun 
617 2018.
618 28 NICE. Multimorbidity: clinical assessment and management. Multimorbidity: assessment, 
619 prioritisation and management of care for people with commonly occurring multimorbidity. NICE 
620 guideline NG56.  Available at: https://www.nice.org.uk/guidance/ng56/evidence. Last access: 10 Jun 
621 2018.
622 29 Bergert FW, Braun M, Ehrenthal K, et al. Recommendations for treating adult and geriatric 
623 patients on multimedication. Int J Clin Pharmacol Ther 2014; 52 Suppl 1: 1-64.
624 30 Peralta-Pedrero ML, Valdivia-Ibarra FJ, Hernandez-Manzano M, et al. [Clinical practice guideline. 
625 Drug prescription in elderly]. Rev Med Inst Mex Seguro Soc 2013; 51: 228-39.
626 31 Scherer M, Wagner H-O, Lühmann D, et al. Multimorbidität S3-Leitlinie: AMWF-Register-Nr. 053-
627 047, DEGAM-Leitlinie Nr. 20. Berlin: Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin 
628 e.V.  Available at: https://www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-
629 Leitlinien/053-047_Multimorbiditaet/053-047l_%20Multimorbiditaet_redakt_24-1-18.pdf. Last access: 
630 10 Jun 2018.
631 32 The Royal Pharmaceutical Society. Medicines optimisation: helping patients make the most of 
632 medicines. .  Available at: 
633 https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Policy/helping-
634 patients-make-the-most-of-their-medicines.pdf. Last access: 28 May 2018.
635 33 Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation. Making it safe and 
636 sound.  Available at: 
637 http://www.kingsfund.org.uk/sites/files/kf/field/field_publication_file/polypharmacy-and-medicines-
638 optimisation-kingsfund-nov13.pdf. Last access: 24 Mar 2017.
Page 69 of 73 Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
25
639 34 Drenth-van Maanen AC, Leendertse AJ, Jansen PAF, Knol W, Keijsers C, Meulendijk MC, van 
640 Marum RJ. The Systematic Tool to Reduce Inappropriate Prescribing (STRIP): Combining implicit and 
641 explicit prescribing tools to improve appropriate prescribing. J Eval Clin Pract 2018; 24: 317-22.
642 35 Hoogendijk EO, van der Horst HE, Deeg DJ, et al. The identification of frail older adults in primary 
643 care: comparing the accuracy of five simple instruments. Age Ageing 2013; 42: 262-5.
644 36 Savva GM, Donoghue OA, Horgan F, O'Regan C, Cronin H, Kenny RA. Using timed up-and-go to 
645 identify frail members of the older population. J Gerontol A Biol Sci Med Sci 2013; 68: 441-6.
646 37 Auyeung TW, Lee JS, Leung J, Kwok T, Woo J. The selection of a screening test for frailty 
647 identification in community-dwelling older adults. J Nutr Health Aging 2014; 18: 199-203.
648 38 Ellis G, Whitehead MA, O'Neill D, Langhorne P, Robinson D. Comprehensive geriatric assessment 
649 for older adults admitted to hospital. Cochrane Database Syst Rev 2011: CD006211.
650 39 Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J 
651 Clin Epidemiol 1992; 45: 1045-51.
652 40 Shekelle PG, MacLean CH, Morton SC, Wenger NS. Acove quality indicators. Ann Intern Med 
653 2001; 135: 653-67.
654 41 Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's 
655 Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J 
656 Clin Pharmacol Ther 2008; 46: 72-83.
657 42 O'mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for 
658 potentially inappropriate prescribing in older people: version 2. Age Ageing 2015; 44: 213-8.
659 43 Renom-Guiteras A, Meyer G, Thurmann PA. The EU(7)-PIM list: a list of potentially inappropriate 
660 medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol 
661 2015; 71: 861-75.
662 44 Kuhn-Thiel AM, Weiss C, Wehling M. Consensus validation of the FORTA (Fit fOR The Aged) List: a 
663 clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging 2014; 31: 
664 131-40.
Page 70 of 73Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
26
665 45 Pazan F, Weiss C, Wehling M. The FORTA (Fit fOR The Aged) List 2015: Update of a Validated 
666 Clinical Tool for Improved Pharmacotherapy in the Elderly. Drugs Aging 2016; 33: 447-9.
667 46 Pazan F, Weiss C, Wehling M. The EURO-FORTA (Fit fOR The Aged) List: International Consensus 
668 Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging 2018; 35: 61-71.
669 47 Arizona Center for Education and Research on Therapeutics (AZCERT). Drugs that Prolong QT & 
670 induce Torsades de Pointes (TdP).  Available at: https://crediblemeds.org/healthcare-providers/. Last 
671 access: 13 Jun 2018.
672 48 Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E. Institute of Medicine. Clinical 
673 Practice Guidelines We Can Trust. Washington, DC: The National Academies Press. 2011.
674 49 Young J, Meagher D, Maclullich A. Cognitive assessment of older people. BMJ 2011; 343: d5042.
675 50 Mounce LTA, Price S, Valderas JM, Hamilton W. Comorbid conditions delay diagnosis of 
676 colorectal cancer: a cohort study using electronic primary care records. Br J Cancer 2017; 116: 1536-43.
677 51 Muth C, Kirchner H, van den Akker M, Scherer M, Glasziou PP. Current guidelines poorly address 
678 multimorbidity: pilot of the interaction matrix method. J Clin Epidemiol 2014; 67: 1242-50.
679 52 Beswick AD, Rees K, Dieppe P, Ayis S, Gooberman-Hill R, Horwood J, Ebrahim S. Complex 
680 interventions to improve physical function and maintain independent living in elderly people: a 
681 systematic review and meta-analysis. Lancet 2008; 371: 725-35.
682 53 Starfield B, Lemke KW, Bernhardt T, Foldes SS, Forrest CB, Weiner JP. Comorbidity: implications 
683 for the importance of primary care in 'case' management. Ann Fam Med 2003; 1: 8-14.
684 54 Starfield B, Lemke KW, Herbert R, Pavlovich WD, Anderson G. Comorbidity and the use of 
685 primary care and specialist care in the elderly. Ann Fam Med 2005; 3: 215-22.
686 55 Starfield BH, Simborg DW, Horn SD, Yourtee SA. Continuity and coordination in primary care: 
687 their achievement and utility. Med Care 1976; 14: 625-36.
688 56 Smith SM, Wallace E, O'Dowd T, Fortin M. Interventions for improving outcomes in patients with 
689 multimorbidity in primary care and community settings. Cochrane Database Syst Rev 2016; 3: CD006560.
Page 71 of 73 Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
27
690 57 Morris RL, Sanders C, Kennedy AP, Rogers A. Shifting priorities in multimorbidity: a longitudinal 
691 qualitative study of patient's prioritization of multiple conditions. Chronic Illn 2011; 7: 147-61.
692 58 Kahneman D, Tversky A. Prospect Theory: An Analysis of Decision under Risk.  Econometrica. 
693 1979; 263-92.
694 59 Verma AA, Razak F, Detsky AS. Understanding choice: why physicians should learn prospect 
695 theory. JAMA 2014; 311: 571-2.
696 60 Dierckx K, Deveugele M, Roosen P, Devisch I. Implementation of shared decision making in 
697 physical therapy: observed level of involvement and patient preference. Phys Ther 2013; 93: 1321-30.
698 61 Fried TR, Tinetti ME, Iannone L, O'Leary JR, Towle V, Van Ness PH. Health outcome prioritization 
699 as a tool for decision making among older persons with multiple chronic conditions. Arch Intern Med 
700 2011; 171: 1854-6.
701 62 Mangin D, Stephen G, Bismah V, Risdon C. Making patient values visible in healthcare: a 
702 systematic review of tools to assess patient treatment priorities and preferences in the context of 
703 multimorbidity. BMJ Open 2016; 6: e010903.
704 63 Vermunt N, Harmsen M, Westert GP, Olde Rikkert MGM, Faber MJ. Collaborative goal setting 
705 with elderly patients with chronic disease or multimorbidity: a systematic review. BMC Geriatr 2017; 17: 
706 167.
707
708
Page 72 of 73Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
28
709 Figures, Tables and Web-Supplements
710
711 Figure 1: Results of the search and selection process (flow chart)
712 Figure 2: Distribution of recommendations per topic and guideline
713
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